Tyrosine Kinase Inhibitors BCL Inhibitors Chemotherapy DNA Epigenetics CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Cyclin Dependent Kinase Inhibitors Serine-Threonine Kinase Inhibitors Other RAR/RXR | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myeloid Leukemia | Estrogen Receptor Positive Breast Cancer | Chronic Lymphocytic Leukemia |
---|---|---|---|---|---|
ruxolitinib | |||||
venetoclax | |||||
HAG + azacitidine | |||||
pembrolizumab | |||||
nivolumab | |||||
venetoclax + azacitidine | |||||
azacitidine | |||||
cytarabine + decitabine + tretinoin | |||||
sintilimab | |||||
venetoclax + decitabine/cedazuridine | |||||
nilotinib | |||||
DSP-2033 | |||||
Tyrosine kinase inhibitor | |||||
TP-0903 | |||||
gemtuzumab ozogamicin | |||||
cytarabine | |||||
CDK4 inhibitor + CDK6 inhibitor |